Clinical Trial Update: A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating the monoclonal antibody KW-2871 in patients with Stage IV melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KW-2871

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Stage IV Melanoma | Phase 1, Phase 2 | Status: TERMINATED